Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

With SMA treatment, it looks like Biogen has another blockbuster drug

By , Globe Staff

Early sales of Biogen Inc.’s new drug to treat spinal muscular atrophy appear to be stronger than industry analysts expected.

Biogen says study shows its drug helps older children with spinal muscular atrophy

By , Globe Staff

The Cambridge biotech on Monday released data from a late-stage clinical trial of Spinraza.

Biotechs take lead in a new push against neurological disorders

By , Globe Staff

Local biotechs are developing drugs for neurological disorders like Alzheimer’s and Huntington’s diseases.

Vertex CEO’s pay falls 38% to $17.4m in second straight decline

By , Globe Staff

Jeffrey M. Leiden’s compensation fell 38 percent in 2016, mostly on a cut in his stock-option awards.